Treatment with pembrolizumab plus axitinib improved response and survival compared with sunitinib in patients with advanced, or metastatic clear-cell renal cell carcinoma.
Read more
This video reviews various trials that aimed to improve outcomes or minimize toxicities among patients receiving adjuvant treatment for HER2-positive breast cancer.
Read more
This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.
This email was sent by: UBM Medica, a divsion of UBM Americas
535 Connecticut Avenue, Suite 300
Norwalk, CT, 06854, USA
